cancervaccine

🚨 $MRNA
— CANCER VACCINE MILESTONE

$MRNA has more than doubled since mid-August, fueled by the Moderna–Merck cancer vaccine Phase 3 success.

🔥 This marks a major milestone: the first Phase 3 efficacy readout for a therapeutic cancer vaccine.

📈 The move highlights how powerful clinical breakthroughs can be for biotech valuations.

👀 $MRNA remains one to watch as the market continues to price in the potential impact of this breakthrough.

#MRNA #Biotech #CancerVaccine #StocksToBinance

Can it bring a greater good news for humanity—will there be more cures for cancer?

This round of gains for Moderna is textbook-level good news followed by high-level consolidation.

On 8/19, Wednesday, Moderna and Merck (MSD) released Phase 3 clinical data for an mRNA melanoma vaccine—this is the world’s first personalized mRNA cancer therapy to pass Phase 3 trials, a groundbreaking milestone. After the news broke, the stock surged directly from around $63 in pre-market trading on Tuesday, topping out at $176.66 during the session and setting a 52-week high. At one point, the intraday gain exceeded 180%.

What’s truly impressive is what happened in the days after the announcement. The stock didn’t crash back to the starting point in a single, typical “sell after the hype” move. Instead, after reaching the $176.66 peak, it spent nearly a week repeatedly trading and consolidating in the $130–$150 range, closing at $139.10 on 8/24. By calculation, it retraced more than 21% from the high, but the cumulative rise over five days was still as high as more than 120%.

This suggests the market’s reaction is more nuanced than simply “hype it up and run.” Early speculative capital did take profits near the peak, but the stock didn’t collapse back to the launch level. That indicates some investors believe this milestone event has real long-term value and are willing to pick up shares on pullbacks.

The harsh reality in biotech is that success in Phase 3 clinical trials is only the beginning. From FDA formal approval to going to hospitals and generating revenue, there’s still a long path of regulatory reviews and commercialization processes to go through. Merck’s Keytruda is the established standard treatment for post-surgery melanoma. This combination therapy has shown it can delay recurrence and reduce the risk of metastasis. These are solid clinical data, not just an imaginative space.

The fact that the stock keeps tugging higher and lower at high levels rather than plunging straight down, to some extent, indicates the market is repricing Moderna’s oncology pipeline. It’s no longer treating it solely as a company whose COVID-vaccine business is in decline. Next, we need to watch the FDA review progress, as well as follow-up trial data for this personalized mRNA platform in other cancer types such as non-small-cell lung cancer—whether it can replicate the success this time.

From a surge of 180% to a pullback and consolidation of more than 21% at the high end, do you think this is the market finding a reasonable valuation after speculative capital retreats—or that the long-term value of this once-in-an-era breakthrough hasn’t been fully reflected yet?

$MRNA $MRK #美股 #生技股 #CancerVaccine

🚨HUGE: Moderna $MRNA plunges 17% after Phase 3 cancer vaccine data leaks two days early, even though the full results are positive.
Shares fell as much as 25% on Thursday, with trading halted for volatility, after partial Phase 3 data for its personalized melanoma vaccine, intismeran, showed up online ahead of Saturday's ESMO presentation in Madrid. The stock closed down about 17.6% at $202.63, one day after hitting a 52-week high of $254.48.
The leaked headline number was a 42% cut in the risk of melanoma returning or death when added to Merck's Keytruda, versus the 49% seen in the earlier, much smaller Phase 2b trial. The full results released later Thursday confirmed it: a hazard ratio of 0.58 with a p-value below 0.001 across 1,137 patients, plus a 38% reduction in distant spread or death. The data has also been accepted by the New England Journal of Medicine.
So why the plunge? Expectations. Moderna was up more than 530% this year, and CNBC noted shares trade on an enormous valuation riding almost entirely on this cancer program. Bernstein called it a "sell the news" event despite a "strong Phase 3 result."
Cross-trial comparisons like 42% versus 49% aren't apples to apples. The Phase 2b trial was a fraction of the size with five years of follow-up, versus 24.6 months here.
The real test comes Saturday, when the full dataset is presented at ESMO.
#Moderna #MRNA #CancerVaccine #Biotech #StockMarket $MRNA